Investor Hub
We are the world's first molecular MRI developer.
We are advancing our MagSense® imaging agent portfolio in clinical development to change the way we look at cancer.
Imagion Biosystems’ innovative medical imaging technology uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Our proprietary MagSense® technology is non-invasive and non-radioactive, providing more specific and accurate detection of cancer than current imaging technologies.
We have multiple commercial opportunities with our SPIONS (superparamagnetic iron oxide nanoparticles) including our proprietary MagSense® imaging technology.
Join our interactive Investor Hub
NEW! Engage with us directly by asking questions, watching video summaries, and be part of our shareholder community.
Investment Highlights
Listed on the ASX: June 2017
R&D operations: San Diego
Registered office: Melbourne
A clinical stage radiopharamaceutical company developing bio-safe, molecularly targeted MRI contrast agents.
- MagSense: SPIONS coated for biocompatibility and targeted by conjugated antibodies to detect cancer tumors
Earlier, more specific detection of cancers
- One in three people impacted by cancer
- Over $100B spent annual in cancer diagnosis but still unable to noninvasively diagnosis tumors
- Current medical imaging technologies invented more than 50 years ago
MagSense® technology will transform cancer diagnosis
- Does not require radioactivity
- Uses bio-safe superparamagnetic nanoparticles
- Targeting moieties include antibodies, antibody fragments, peptides, or small molecules
Multiple revenue opportunities
- High gross-margin proprietary molecular imaging agents
- Other biomedical applications enabled with customer supply agreements in place for use in their medical products
Strong leadership and advisory board
- Experienced and skill diverse board of directors and management team
- Scientific advisory board with collective expertise in oncology, medical imaging, nanotechnology and clinical trial design
IBX Share Price History
Investment Quick Links
The Annual Report is a concise document which includes highlights of the relevant fiscal year’s progress, an update of our products in
development, an overview of operations and summary financial data.
Recent
Latest News
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
[VIDEO] EGM Recording – 13 November 2023
https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is
Quarterly Activity Report – Quarter ending 30 September 2023
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Investor Services
Investors seeking information regarding their shareholding or dividends or wishing to advise of a change of address should contact Boardroom Pty Limited at:
Boardroom Pty Limited
Level 12, 225 George Street,
Sydney, NSW, 2000
Telephone: (02) 9290 9600 Facsimile: (02) 9279 0664 or
Visit the online service at www.boardroomlimited.com.au
Boardroom Pty Limited has an online service for investors called InvestorServe. This enables investors to make online changes, view balances and transaction history, as well as obtain information about recent dividend payments and download various forms to assist in the management of their holding.
To request listed option conversion forms, please email Boardroom at: corporateactions@boardroomlimited.com.au